{"title": "Medication Safety Resources | Pharmacovigilance", "author": null, "url": "https://www.ihs.gov/nptc/pharmacovigilance/medication-safety-resources/", "hostname": "ihs.gov", "description": "The Indian Health Service (IHS), an agency within the Department of Health and Human Services, is responsible for providing federal health services to American Indians and Alaska Natives. The provision of health services to members of federally-recognized Tribes grew out of the special government-to-government relationship between the federal government and Indian Tribes. The IHS is the principal federal health care provider and health advocate for Indian people, and provides a comprehensive health service delivery system for American Indians and Alaska Natives. The IHS Mission is to raise the physical, mental, social, and spiritual health of American Indians and Alaska Natives to the highest level.", "sitename": "National Pharmacy & Therapeutics Committee", "date": "2017-01-01", "cleaned_text": "be offline for approximately 4 hours starting at 7 PM ET on Thursday, September 7th for planned maintenance. We apologize for any inconvenience. Medication Safety Resources Recent Safety Resources Important FDA communications regarding the prescribing and monitoring of FDA approved medications and devices are listed here. Drug Safety Communications (DSC) are the result of pharmacovigilance through clinical research findings and post marketing surveillance data. A listing of recent DSC can be found on the [FDA website ](https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications) Drug Safety Alerts (DSAs) provide important information about the safe and effective use of one or more medications. Drug safety alerts provide information about current topics and findings to help raise awareness and promote medication safety. Stay Connected Sign up on our [NPTC LISTSERV](/listserv/topics/signup/?list_id=183) for latest news, updates, discussions, and drug safety alerts and communications. CDC Health Update: Potential Risk for New Mpox Cases Drug-Safety Alert May 15, 2023 The Centers for Disease Control and Prevention (CDC) released a Health Advisory Network (HAN) Health Update to raise awareness that although cases of mpox (formerly monkeypox) have declined, the CDC continues to receive reports of cases that reflect ongoing community transmission in the United States and internationally. Vaccination continues to be one of the most important prevention measures. Patients with mpox benefit from supportive care and pain control and may be eligible for tecovirimat and JYNNEOS therapies. [Read More](/nptc/pharmacovigilance/medication-safety-resources/cdc-health-update-potential-risk-for-new-mpox-cases/) FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions Drug-Safety CommunicationMay 11, 2023 The U.S. Food and Drug Administration (FDA) released a drug safety communication to address continuing concerns of misuse, abuse, addiction, and overdose of prescription stimulants. The FDA is requiring updates to the Boxed Warning and other information to ensure the prescribing information is made consistent across the entire class of these medicines. Updated Boxed Warning information will describe the risks of misuse, abuse, addiction, and overdose consistently across all medicines in the class and advise heath care professionals to monitor patients closely for signs and symptoms of misuse, abuse, and addiction. [Read More](/nptc/pharmacovigilance/medication-safety-resources/fda-updating-warnings-to-improve-safe-use-of-prescription-stimulants-used-to-treat-adhd-and-other-conditions/) FDA Updates Prescribing Information for all Opioid Pain Medicines to Provide Additional Guidance for Safe Use Drug-Safety CommunicationApril 14, 2023 The FDA recently released a Drug Safety Communication to raise awareness that there are updates to prescribing information for all opioid pain medications in an effort to improve the safe use of these medications. [Read More](/nptc/pharmacovigilance/medication-safety-resources/fda-updates-prescribing-information-for-all-opioid-pain-medicines-to-provide-additional-guidance-for-safe-use/) DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine Drug-Safety Alert March 22, 2023 The Drug Enforcement Agency (DEA) issued a Public Safety Alert to warn the American public of a sharp increase in the trafficking of fentanyl mixed with xylazine. Xylazine, also known as \"Tranq,\" is a powerful sedative that the U.S. Food and Drug Administration has approved for veterinary use. The DEA has seized xylazine and fentanyl mixtures in 48 of 50 States. The DEA Laboratory System is reporting that in 2022 approximately 23% of fentanyl powder and 7% of fentanyl pills seized by the DEA contained xylazine. [Read More](/nptc/pharmacovigilance/medication-safety-resources/dea-reports-widespread-threat-of-fentanyl-mixed-with-xylazine/) Outbreak of Extensively Drug-resistant Pseudomonas aeruginosa Associated with EzriCare Artificial Tears Drug-Safety Alert February 2, 2023 The Centers for Disease Control and Prevention (CDC) issued a Health Advisory to inform patients and clinicians of potential contamination of EzriCare Artificial Tears with a rare strain of extensively drug-resistant P. aeruginosa. [Read More](/nptc/pharmacovigilance/medication-safety-resources/extensively-drug-resistant-pseudomonas-aeruginosa-associated-with-ezricare-artificial-tears/) Increase in Pediatric Invasive Group A Streptococcal Infections Drug-Safety Alert December 22, 2022 The Centers for Disease Control and Prevention (CDC) issued a Health Advisory to notify clinicians and public health authorities of a recent increase in pediatric invasive group A streptococcal (iGAS) infections. [Read More](/nptc/pharmacovigilance/medication-safety-resources/increase-in-pediatric-invasive-group-a-streptococcal-infections/) Interim Guidance for Clinicians to Prioritize Antiviral Treatment of Influenza in the Setting of Reduced Availability of Oseltamivir Drug-Safety AlertDecember 15, 2022 The Centers for Disease Control and Prevention (CDC) issued a Health Advisory to provide guidance on antiviral treatment of influenza in the setting of reduced availability of oseltamivir. [Read More](/nptc/pharmacovigilance/medication-safety-resources/interim-guidance-for-clinicians-to-prioritize-antiviral-treatment-of-influenza-in-the-setting-of-reduced-availability-of-oseltamivir/) Risk of severe hypocalcemia in patients on dialysis receiving denosumab Drug-Safety CommunicationNovember 22, 2022 FDA is investigating the risk of severe hypocalcemia with serious outcomes, including hospitalization and death, in patients with advanced kidney disease on dialysis treated with the osteoporosis medicine denosumab (Prolia\u00ae). [Read More](/nptc/pharmacovigilance/medication-safety-resources/risk-of-severe-hypocalcemia-in-patients-on-dialysis-receiving-denosumab/) Report Potential JYNNEOS Adverse Vaccine Events to VAERS Drug-Safety AlertSeptember 1, 2022 Vaccination providers who are administering JYNNEOS under the EUA are required to report adverse events that occur afterward. [Read More](/nptc/pharmacovigilance/medication-safety-resources/report-potential-jynneos-adverse-vaccine-events-to-vaers/) Possible increased risk of death, serious side effects with duvelisib (Copiktra) Drug-Safety CommunicationJune 30, 2022 The FDA warns of a possible increased risk of death with the cancer drug, duvelisib (Copiktra) used in the treatment of relapsed or refractory leukemia (CLL) or small to Safety Concerns Drug-Safety CommunicationJune 1, 2022 The FDA is withdrawing its approval for the cancer medicine Ukoniq (umbralisib). Ukoniq was approved to treat two specific types zone lymphoma (MZL) Treatment May 25, 2022 Drug-Safety Alert The Centers for Disease Control and Prevention (CDC) released a Health Advisory Network (HAN) Health Advisory on the potential for recurrence of COVID-19 or \"COVID-19 rebound.\" [Read More](/nptc/pharmacovigilance/medication-safety-resources/covid-19-rebound-after-paxlovid-treatment/) Additional Paxlovid Dose Packs Authorized for Patients with Moderate Renal Impairment Drug-Safety AlertApril 15, 2022 The FDA revised the EUA for Paxlovid, authorizing an additional dose pack with appropriate dosing for patients with moderate renal impairment. [Read More](/nptc/pharmacovigilance/medication-safety-resources/additional-paxlovid-dose-packs-authorized-for-patients-with-moderate-renal-impairment/) FDA: Monitor Babies & Young Children Who Receive Injections of Iodine-Containing Contrast Media Drug-Safety CommunicationMarch 30, 2022 The FDA recommends that newborns and children through 3 years old have thyroid monitoring within 3 weeks post-injection of iodinated contrast media for medical imaging procedures. [Read More](/nptc/pharmacovigilance/medication-safety-resources/fda-monitor-babies-young-children-who-receive-injections-of-iodine-containing-contrast-media/) Possible Increased Risk for Death with Umbralisib (Ukoniq) Drug-Safety CommunicationFebruary 3, 2022 The FDA released a warning of possible increased risk of death with umbralisib (Ukoniq) used for the treatment of lymphoma. [Read More](/nptc/pharmacovigilance/medication-safety-resources/possible-increased-risk-for-death-with-umbralisib-ukoniq/) Dental Problems Have Been Reported with Medicines Containing Buprenorphine that are Dissolved in the Mouth Drug-Safety CommunicationJanuary 12, 2022 The dental problems, including tooth decay, cavities, oral infections, and loss of teeth, can be serious and have been reported even in patients with no history of dental "}